|
Population
|
Adult patients (≥18 years of age) with moderate-to-severe chronic plaque psoriasis |
Children younger than 18 years |
|
Intervention
|
Tildrakizumab (Ilumetri®) (100 mg Week 0, 4, Q12W)
Guselkumab (Tremfya®) (100 mg Week 0, 4, Q8W)
|
Studies without either of these interventions |
|
Comparators
|
Placebo
Best supportive carea
|
NA |
|
Outcomes
|
Severity of psoriasis: PASI 75 or 90
Frequency of Serious Adverse Events
Withdrawals for any cause
Outcomes based on ITT analysis
|
NA |
|
Study Design
|
Phase III RCTs |
Phase I, II, or IV RCTs
Case studies
Case reports
Nonrandomized, controlled trials
Reviews, including systematic reviews
Observational studies
|
|
Limits
|
English language publications only
Studies published as full text articles in peer review journals
|
Non-English language publications
Conference abstracts
|